Media Coverage
Read how VistaGen’s intention to revolutionize mental health medicine is causing a buzz in the media.
An interview with Shawn Singh: Chief Executive Officer and Director of VistaGen Therapeutics
VistaGen’s Antidepressant Nasal Spray Succeeds Phase 2a Trial
FDA Clears Way for Phase 2 Trial of AV-101 for Levodopa-Induced Dyskinesia
Investigational Dyskinesia Treatment Gets FDA Green Light
VistaGen to study dyskinesia drug in Phase II Parkinson’s trial
FDA Clears Study to Test New Drug to Treat Dyskinesia for Parkinson Patients
Intranasal Therapy Fast-Tracked for Social Anxiety Disorder
Long-Term Use of Benzodiazepines – Avoiding Another Drug Crisis
Advancing AV-101
